ATAC
adjuvant trial: Arimidex versus Tamoxifen versus the Combination
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 1 2000
Play
Audio Below:
There
are multiple sub protocols, and one of the questions is going to
be that of bone. I mean, tamoxifen is an excellent anti-osteoporosis
agent. It may not have the criteria for getting FDA approval for
it, but it sure is pretty good, and so we want to know what the
effect is on bone. Then, there is the issue of uterine cancer. I
don’t think clinically it’s that big an issue, but I think
from the point of view of the patients, and the general medical
community and biases, we need to know that. There is a quality of
life part of the study. Quality life studies are only as good as
the instruments that are used to measure them, and I’m not,
you know, I’m just not sure what we will learn, even if there
is a difference or no difference. That’s very, very, very interesting,
there is a pharmacokinetic study in there too, which you know, one
always want to know what the PK is, but I’m not sure that’s
going to make a difference as much as the clinical result will be.
It is a very important study, and for the reasons you said, not
just because of having another agent in terms of efficacy, but in
terms of quality of life.
